Združene države Amerike - angleščina - NLM (National Library of Medicine)

sagent pharmaceuticals - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections, including pneumonia, caused by pseudomonas aeruginosa and other pseudomonas spp.; haemophilus influenzae, including ampicillin-resistant strains; klebsiella spp.; enterobacter spp.; proteus mirabilis; escherichia coli; serratia spp.; citrobacter spp.; streptococcus pneumoniae; and staphylococcus aureus (methicillin-susceptible strains). - skin and skin-structure infections caused by pseudomonas aeruginosa; klebsiella spp.; escherichia coli; proteus spp., including proteus mirabilis and indole-positive proteus; enterobacter spp.; serratia spp.; staphylococcus aureus (methicillin-susceptible strains); and streptococcus pyogenes (group a beta-hemolytic streptococci). - urinary tract infections, both complicated and uncomplicated, caused by pseudomonas aeruginosa; enterobacter s

Združene države Amerike - angleščina - NLM (National Library of Medicine)

sagent pharmaceuticals - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections, including pneumonia, caused by pseudomonas aeruginosa and other pseudomonas spp.; haemophilus influenzae, including ampicillin-resistant strains; klebsiella spp.; enterobacter spp.; proteus mirabilis; escherichia coli; serratia spp.; citrobacter spp.; streptococcus pneumoniae; and staphylococcus aureus (methicillin-susceptible strains). - skin and skin-structure infections caused by pseudomonas aeruginosa; klebsiella spp.; escherichia coli; proteus spp., including proteus mirabilis and indole-positive proteus; enterobacter spp.; serratia spp.; staphylococcus aureus (methicillin-susceptible strains); and streptococcus pyogenes (group a beta-hemolytic streptococci). - urinary tract infections, both complicated and uncomplicated, caused by pseudomonas aeruginosa; enterobacter spp.; pr

Združene države Amerike - angleščina - NLM (National Library of Medicine)

sagent pharmaceuticals - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections , including pneumonia, caused by pseudomonas aeruginosa and other pseudomonas spp.; haemophilus influenzae, including ampicillin-resistant strains; klebsiella spp.; enterobacter spp.; proteus mirabilis; escherichia coli; serratia spp.; citrobacter spp.; streptococcus pneumoniae; and staphylococcus aureus (methicillin-susceptible strains). - skin and skin-structure infections caused by pseudomonas aeruginosa; klebsiella spp.; escherichia coli; proteus spp., including proteus mirabilis and indole-positive proteus; enterobacter spp.; serratia spp.; staphylococcus aureus (methicillin-susceptible strains); and streptococcus pyogenes (group a beta-hemolytic streptococci). - urinary tract infections, both complicated and uncomplicated, caused by pseudomonas aeruginosa; enterobacter spp.; proteus spp., including proteus mirabilis and indole-positive proteus; klebsiella spp.; and escherichia coli. - bacterial septicemia caused by pseudomonas aeruginosa, klebsiella spp., haemophilus influenzae , escherichia coli , serratia spp., streptococcus pneumoniae , and staphylococcus aureus (methicillin-susceptible strains). - bone and joint infections caused by pseudomonas aeruginosa, klebsiella spp., enterobacter spp., and staphylococcus aureus (methicillin-susceptible strains). - gynecologic infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by escherichia coli. - intra-abdominal infections, including peritonitis caused by escherichia coli, klebsiella spp., and staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and bacteroides spp. (many strains of bacteroides fragilis are resistant). - central nervous system infections, including meningitis, caused by haemophilus influenzae and neisseria meningitidis. ceftazidime has also been used successfully in a limited number of cases of meningitis due to pseudomonas aeruginosa and streptococcus pneumoniae . ceftazidime for injection, usp may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. ceftazidime for injection, usp may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. the dose depends on the severity of the infection and the patient's condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, usp and other antibacterial drugs, ceftazidime for injection, usp should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftazidime for injection is contraindicated in patients who have shown hypersensitivity to ceftazidime or the cephalosporin group of antibacterial drugs. ceftazidime for injection, usp instructions for constitution pharmacy bulk package: 6 g - insert the syringe needle through the vial closure and inject 26 ml of diluent. the vacuum may assist entry of the diluent. remove the syringe needle. - shake to dissolve; a clear solution containing approximately 1 g of ceftazidime activity per 5 ml will be obtained in 1 to 2 minutes. - insert a gas-relief needle through the vial closure to relieve the internal pressure. remove the gas-relief needle before extracting any solution. note: to preserve product sterility, it is important that a gas-relief needle is not inserted through the vial closure before the product has dissolved. sagent® mfd. for sagent pharmaceuticals schaumburg, il 60195 (usa) made in brazil ©2020 sagent pharmaceuticals, inc. revised: june 2020 sagent pharmaceuticals®

Malta - angleščina - Medicines Authority

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - ceftazidime pentahydrate - powder for solution for injection - ceftazidime pentahydrate 500 mg - antibacterials for systemic use

Malta - angleščina - Medicines Authority

hospira uk limited horizon, honey lane, hurley, maidenhead sl6 6rj, united kingdom - ceftazidime pentahydrate - powder for solution for infusion or injection - ceftazidime pentahydrate 1.165 g - antibacterials for systemic use

Malta - angleščina - Medicines Authority

hospira uk limited horizon, honey lane, hurley, maidenhead sl6 6rj, united kingdom - ceftazidime pentahydrate - powder for solution for injection/infusion - ceftazidime pentahydrate 2.330 g - antibacterials for systemic use

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - avibactam sodium, quantity: 543.5 mg (equivalent: avibactam, qty 500 mg); ceftazidime pentahydrate, quantity: 2329.7 mg (equivalent: ceftazidime, qty 2000 mg) - injection, powder for - excipient ingredients: sodium carbonate - zavicefta is indicated for the treatment of the following infections in adults (see sections 4.4 special warnings and precautions for use and 5.1 pharmacodynamic properties):,? complicated intra-abdominal infection (ciai) in combination with metronidazole. ? complicated urinary tract infection (cuti) including pyelonephritis.,? hospital-acquired pneumonia (hap) including ventilator associated pneumonia (vap).,zavicefta is indicated for the treatment of the following infections in infants and paediatric patients (greater than or equal to 3 months to < 18 years) (see sections 4.4 special warnings and precautions for use and 5.1 pharmacodynamic properties):,? complicated intra-abdominal infection (ciai) in combination with metronidazole. ? complicated urinary tract infection (cuti) including pyelonephritis.,consideration should be given to official guidance on the appropriate use of antibacterial agents.,to reduce the development of drug-resistant bacteria and maintain the effectiveness of zavicefta and other antibiotics, zavicefta should be used in combination with an antibacterial agent(s) active against gram-positive and/or anaerobic pathogens when these are known or suspected to be contributing to the infectious process.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime;  ;   - powder for injection - 1 g - active: ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime     excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 291mg equivalent to 250 mg ceftazidime;   - powder for injection - 250 mg - active: ceftazidime pentahydrate 291mg equivalent to 250 mg ceftazidime   excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 2.328 g equivalent to 2g ceftazidime;  ;   - powder for injection - 2 g - active: ceftazidime pentahydrate 2.328 g equivalent to 2g ceftazidime     excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)